research 5α-reductase activity in the prostate
Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
Search
for
Sort by
Research
720-750 / 1000+ results research Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment
Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.
research Editorial Comment
Self-management can help improve symptoms of benign prostatic hyperplasia.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research MP24-09 MEN WITH AN IMPROVEMENT IN URINARY SYMPTOMS HAVE A LOWER RISK OF MORTALITY
Men with better urinary symptoms have a lower risk of death.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
research (163) Cutting Costs, Not Care: New Models for Affordable Men’s Health Medications
Using Mark Cuban Cost Plus Drug Company can save money on men's health medications compared to Medicare.
research The neurosteroidogenic enzyme 5α-reductase modulates the role of D1 dopamine receptors in rat sensorimotor gating
5α-reductase affects dopamine receptors linked to sensorimotor gating, which may help understand disorders like schizophrenia.
research ダブルストロボレンジファインダの開発(特別講演)(画像センシングおよび一般)
Some prostate cancers have gene changes that may affect treatment with certain drugs.
research Les Visiteurs des malades
5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
research Cutting Costs, Not Care: New Models for Affordable Men’s Health Medications
CPDC offers significant cost savings on men's health medications compared to Medicare and GoodRx.
research MP09-17 METHYLATION OF SRD5A2 IN THE BLOOD AS A NOVEL BIOMARKER TO PREDICT SENSITIVITY TO 5-ARI TREATMENT
SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
research Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents
Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
research Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia
Higher levels of miR-1199-5p may reduce the effectiveness of certain prostate treatments.
research Plasma androsterone/epiandrosterone sulfates as markers of 5α-reductase activity: Effect of finasteride in normal men
Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.
research Thrombotic risk minimization for D iane‐35 and generics
The use of Diane-35 and its generics significantly decreased in the Netherlands.
research Medikamentöse Therapie der BPH Ist eine Kombinationstherapie mit 5α-Reduktasehemmern und α-Rezeptorenblockern sinnvoll?
Combination therapy is more effective for prostate volumes over 60 ml.
research 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
research PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION
Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
research MP85-05 SEXUAL DYSFUNCTION AFTER 5-ALPHA REDUCTASE INHIBITOR USE: INSIGHTS FROM THE REDUCE STUDY GROUP DATABASE
Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.
research 1424 METHYLATION AND DECREASED EXPRESSION OF 5-ALPHA REDUCTASE 2 IN HUMAN PROSATE SAMPLES: IMPLICATIONS FOR RESISTANCE TO THERAPY FOR BPH
Methylation of the 5-AR2 gene may cause resistance to Finasteride in BPH patients.
research Control of testosterone 5alpha-reductase activity in the human hyperplastic prostate
Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.
research Effects of 5-?±-Reductase Inhibitor (Finasteride) on Per Operative Blood Loss in Patients with BPH undergoing TURP
Finasteride reduces blood loss and the need for blood transfusions during and after TURP surgery.
research A pharmacovigilance study of drug‐reduced male semen quality based on the Food and Drug Administration adverse event reporting system database
Some drugs can reduce male semen quality.
research The relevance of using 5α-reductase inhibitors in the conservative management of benign prostatic hyperplasia: A review
5α-reductase inhibitors help manage symptoms of benign prostatic hyperplasia and may also prevent prostate cancer and treat hair loss.
research Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial
The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
research L'etude PCPT : regards d'un urologue intéressé
Finasteride may reduce prostate cancer risk.
research Alpha Blocker and 5-Alpha Reductase Inhibitor Prescribing Habits among Urologists and Primary Care Physicians
Urologists prescribe newer medications more often than primary care physicians, who could benefit from more education on treatment options.